Loading…
Lakefront Biotherapeutics NV is projected to rise to $36.44 by 2027, a +32% move from its current price of $27.64. LKFT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $27.33 | $27.65 | $27.98 | +0.05% |
| Aug 2 | $27.22 | $27.67 | $28.13 | +0.10% |
| Aug 3 | $27.13 | $27.68 | $28.24 | +0.15% |
| Aug 4 | $27.06 | $27.70 | $28.35 | +0.20% |
| Aug 5 | $27.00 | $27.71 | $28.44 | +0.25% |
| Aug 6 | $26.95 | $27.72 | $28.52 | +0.31% |
| Aug 7 | $26.90 | $27.74 | $28.60 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.90 | $27.74 | $28.60 | +0.36% |
| Week 2 | $26.65 | $27.84 | $29.07 | +0.72% |
| Week 3 | $26.49 | $27.94 | $29.46 | +1.07% |
| Week 4 | $26.37 | $28.04 | $29.81 | +1.44% |
| Week 5 | $26.27 | $28.14 | $30.14 | +1.80% |
| Week 6 | $26.19 | $28.24 | $30.44 | +2.16% |
| Week 7 | $26.13 | $28.34 | $30.74 | +2.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lakefront Biotherapeutics NV is a biotechnology company focused on developing medicines in oncology and immunology, with activities primarily in the United States and Europe. LKFT operates in the Healthcare sector and has a pipeline that includes GLPG3667 in a phase 2 trial for dermatomyositis and systemic lupus erythematosus, GLPG5101 a CD19 CAR-T candidate in a phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma, and GLPG5301 a BCMA CAR-T candidate in phase 1/2 for relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc. It was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. Lakefront Biotherapeutics NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
LKFT is currently trading at $28.12 per share with a market capitalization of $1.84B. The stock is ranked 2054 in size.
The near-term outlook shows a neutral stance for 2026, with a 2026 price forecast that averages $28.12 and spans from a low of $26.61 to a high of $36.70, and an implied ROI of 0%.
From 2027 onward, the forecast turns bullish, with rising average prices and higher ROIs through 2050. The 2030 average is $46.57 with a 65.6% ROI, and the 2050 average is $190.98 with a 579.2% ROI, indicating substantial long‑term upside under the projected trajectory.
A major floor 7.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 15.4% above — clearing it would confirm fresh momentum.
Key LKFT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LKFT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.90 | Sell | $27.96 | Sell |
| MA 10 | $28.46 | Sell | $28.36 | Sell |
| MA 20 | $29.30 | Sell | $28.77 | Sell |
| MA 50 | $28.73 | Sell | $28.96 | Sell |
| MA 100 | $29.11 | Sell | $29.45 | Sell |
| MA 200 | $30.90 | Sell | $30.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.42 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -122.06 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | -6.21 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -1.28 | Sell |
| Ultimate (7,14,28) | 21.01 | Buy |
| Momentum (10) | -1.96 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 27.64 | Buy |
| ADX (14) | 19.02 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bearish. The RSI(14) is 40, and the stock trades near the near-term support of $28.12 with a resistance level at $30.81.
The moving averages show the 50-day simple moving average at $28.67 and the 200-day simple moving average at $31.07. The 30‑day price range spans from a low of $25.86 to a high of $30.58, highlighting sideways to modestly weighted movement in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.61 | $27.64 | $35.60 | 0% | Neutral | |
| $29.88 | $36.44 | $46.44 | +32% | Bullish | |
| $31.74 | $39.45 | $51.65 | +43% | Bullish | |
| $33.27 | $42.00 | $56.18 | +52% | Bullish | |
| $35.23 | $45.07 | $61.38 | +63% | Bullish | |
| $34.53 | $44.71 | $61.86 | +62% | Bullish | |
| $40.60 | $53.17 | $74.62 | +92% | Bullish | |
| $48.34 | $63.98 | $90.96 | +131% | Bullish | |
| $48.54 | $64.88 | $93.35 | +135% | Bullish | |
| $52.43 | $70.75 | $102.93 | +156% | Bullish | |
| $74.38 | $104.70 | $159.63 | +279% | Bullish | |
| $116.69 | $176.17 | $287.95 | +537% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.61 | $27.64 | $32.18 | +0.00% |
| August 2026 | $24.07 | $28.07 | $33.36 | +1.56% |
| September 2026 | $24.69 | $28.95 | $34.73 | +3.15% |
| October 2026 | $24.49 | $28.85 | $34.86 | -0.36% |
| November 2026 | $24.06 | $28.45 | $34.58 | -1.39% |
| December 2026 | $24.55 | $29.13 | $35.60 | +2.39% |
Click any year to see its month-by-month LKFT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lakefront Biotherapeutics NV's 2026 outlook centres on $27.64, within a $26.61 to $35.60 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, LKFT could reach as high as $46.44, with a base case around $36.44 and support toward $29.88 — roughly +32% from $27.64. Buyers look set to stay in control over this stretch.
Expect LKFT to range from $31.74 to $51.65 through 2028. The $39.45 average target implies a +43% move from current prices. That is up +8% on the projected 2027 average. Momentum favours further upside here.
The LKFT price prediction for 2029 points to an average of $42.00 (low $33.27, high $56.18) — a potential gain of +52% on today's $27.64. Buyers look set to stay in control over this stretch.
In 2030, LKFT is projected to trade between $35.23 and $61.38, averaging $45.07 — a potential gain of +63% from today's $27.64. That is up +7% on the projected 2029 average. Momentum favours further upside here.
Lakefront Biotherapeutics NV's 2031 outlook centres on $44.71, within a $34.53 to $61.86 range. That is -1% versus the projected 2030 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, LKFT could reach as high as $74.62, with a base case around $53.17 and support toward $40.60 — roughly +92% from $27.64. Momentum favours further upside here.
Expect LKFT to range from $48.34 to $90.96 through 2033. The $63.98 average target implies a +131% move from current prices. That is up +20% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The LKFT price prediction for 2034 points to an average of $64.88 (low $48.54, high $93.35) — a potential gain of +135% on today's $27.64. Momentum favours further upside here.
In 2035, LKFT is projected to trade between $52.43 and $102.93, averaging $70.75 — a potential gain of +156% from today's $27.64. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Lakefront Biotherapeutics NV's 2040 outlook centres on $104.70, within a $74.38 to $159.63 range. That is up +48% on the projected 2035 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2050, LKFT could reach as high as $287.95, with a base case around $176.17 and support toward $116.69 — roughly +537% from $27.64. Buyers look set to stay in control over this stretch.
Investing $1,000 in LKFT today (≈ 36.17945 LKFT) could be worth
$6,373.57
+$5,373.57 (+537%) by 2050 · US Dollar
Based on the average projected LKFT price of $176.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LKFTwould be worth at today's price.
$1,000 invested in LKFT on Jul 30, 2025 (≈ 30.057108 LKFT) would be worth
$830.78
-$169.22 (-16.9%) today · 0.83× · US Dollar
Based on a LKFT entry price of $33.27 vs. today's $27.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.12 | $982.93 | -1.7% |
| 1 month ago | $29.98 | $921.95 | -7.8% |
| 3 months ago | $28 | $987.14 | -1.3% |
| 6 months ago | $33.88 | $815.82 | -18.4% |
| 1 year ago | $33.27 | $830.78 | -16.9% |
| All time (5.0y) ago | $61.46 | $449.72 | -55.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LKFT forecast.
Our base-case forecast reaches $55.00 around 2033.
Implied market cap at $55.00: $3.6B
The multi-year forecast paints a bullish path from 2027 onward, with the average price rising from $37.34 in 2027 to progressively higher levels through 2050, and corresponding ROIs climbing from 32.8% to 579.2%.
Key milestones include 2030 with an average of $46.57 and a 65.6% ROI, 2032 with an average of $56.32 and a 100.3% ROI, and 2035 with an average of $75.12 and a 167.1% ROI. The forecast also shows a jump to an average of $111.71 in 2040 (ROI 297.3%) and $190.98 in 2050 (ROI 579.2%). These figures reflect a long‑term bullish trajectory accompanied by substantial upside potential, albeit with inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $46.57 with a minimum of $36.39 and a maximum of $63.45, yielding a 65.6% ROI and a bullish sentiment.
Long‑term forecasts turn bullish from 2027 onward, with averages rising to $37.34 (2027), $40.74 (2028), and higher toward $46.57 (2030) and beyond, with ROIs of 32.8%, 44.9%, 65.6%, 297.3%, and 579.2% by 2050. The near term (2026) is neutral, and these are estimates, not guarantees.
Yes. The forecast shows max prices above $100, including $109.30 in 2035, $98.25 in 2034 (just below 100 on that year’s max), $170.35 in 2040, and $312.20 in 2050.
Current price is $28.12 and market cap is $1.84B.
For 2026, the min is $26.61, the average is $28.12, and the max is $36.70. The 30‑day range is $25.86 to $30.58.
Lakefront Biotherapeutics NV Community Discussion
0Share your Lakefront Biotherapeutics NV price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.